FB Bancorp, Inc. FBLA Allowance for Credit Losses on Financing Receivables - Individually Evaluated
Allowance for Credit Losses on Financing Receivables - Individually Evaluated at other companies
Other financials
Where this comes from
Reported directly by FB Bancorp, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinancingReceivableAllowanceForCreditLossesIndividuallyEvaluatedForImpairment1.
The official record: FB Bancorp, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated?
- FB Bancorp, Inc. (FBLA) reported allowance for credit losses on financing receivables - individually evaluated of $1.56M in Q1 2026.
- How has FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated changed year-over-year?
- FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated increased by 0.2% year-over-year, from $1.56M to $1.56M.
- What is the long-term trend for FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated?
- Over 2 years (2023 to 2025), FB Bancorp, Inc.'s allowance for credit losses on financing receivables - individually evaluated has grown at a 40.1% compound annual growth rate (CAGR), from $911K to $1.79M.
- What does allowance for credit losses on financing receivables - individually evaluated mean?
- Represents the specific valuation allowance established for financing receivables that have been individually evaluated for impairment. This metric reflects management's estimate of expected credit losses for loans with unique risk characteristics. It is a critical indicator of the bank's internal credit risk assessment and provisioning adequacy.